SCHEMBL5034756

SCHEMBL5034756

COc1ccc(N(C(=O)c2ccccc2Cl)c2nc(C(=O)NCc3cccc(F)c3)cs2)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
LMNA P02545 3/20 0.43
HSD17B13 Q7Z5P4 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NOD2 Q9HC29 1/20 0.41
PDE10A Q9Y233 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TP53 P04637 1/20 0.40
PTPN7 P35236 1/20 0.40
DUSP3 P51452 1/20 0.40
HTT P42858 2/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
APEX1 P27695 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035133 0.92 HPGD (0.47) HPGDLMNAMEN1KMT2ANOD2
SCHEMBL5032672 0.85 TLR7 (0.40) HPGDLMNAMEN1KMT2ANOD2
SCHEMBL5034854 0.85 HPGD (0.45) HPGDLMNAMEN1KMT2ANOD2
SCHEMBL5032563 0.81 ALDH1A1 (0.47) HPGDLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL5035310 0.79 HPGD (0.40) HPGDLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL5032679 0.79 LMNA (0.47) HPGDLMNASMN1; SMN2HSD17B10TP53
SCHEMBL5034680 0.79 MAPT (0.46) HPGDLMNAMEN1KMT2APDE10A
SCHEMBL5032680 0.78 CES2 (0.41) HPGDLMNASMN1; SMN2MAPTNR1H4
SCHEMBL5034757 0.78 NPC1 (0.44) MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL5032635 0.77 FLT1 (0.40) HPGDLMNAMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
JP-2007513193-A 2007-05-24 JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 HPGD 1922/4885LMNA 4010/4885HSD17B13 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.